TCT-225: Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First- Generation Drug-Eluting Stents in Contemporary Clinical Practice
myocardial infarction, stent thrombosis, TVR). Results: The DES and BMS groups were well matched except that DES patients received dual antiplatelet therapy for a longer duration and had smaller final vessel diameter. In survival analysis, at a mean follow-up of 1333 ± 659 days after PCI, the DES group had similar incidence of death/myocardial infarction (24 vs 27%, log rank p=0.23) and stent thrombosis (4.0 vs 2.6%, p=0.18) as the BMS group. The DES patients had lower incidence of TVR (8.1 vs 17%, p=0.0018) but similar MACE (26 vs 37%, p=0.31). In multivariable analysis, DES vs BMS implantation showed no significant impact on death/myocardial infarction [adjusted hazards ratio (HR) 1.0, 95% confidence intervals (CI) 0.7-1.4], stent thrombosis (HR 1.7; CI 0.7-4.0), or MACE (HR 0.8; CI 0.6-1.1). However, TVR was lower in the DES group (HR 0.4; CI 0.3-0.7). Conclusion: In patients presenting with NSTEMI, DES implantation appears to be as safe as BMS implantation at long-term follow up.